Applications of (S)-(-)-3-Tert-Butoxycarbonyl-4-Formyl-2,2-Dimethyl-1,3-Oxazolidine in Industrial Manufacturing

As an advanced chiral building block, (S)-(-)-3-Tert-Butoxycarbonyl-4-Formyl-2,2-Dimethyl-1,3-Oxazolidine plays an integral role in downstream synthesis across multiple sectors. This section details its concrete industrial applications, highlighting actionable integration points, dosage parameters, compliance boundaries, and ultimate finished goods based on manufacturer feedback and regulatory practice.

1. Chiral Pharmaceutical Intermediate Synthesis

Major pharmaceutical manufacturers queue this oxazolidine derivative into multi-stage syntheses for chiral amine and amino acid derivatives. It serves as a protecting group and aldehyde donor in enantioselective reactions. Integration occurs during the preparation of non-racemic drug actives such as beta-lactam antibiotics and oxazolidinone-based agents, driving precise stereochemical outcomes within GMP-regulated environments.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP–NF Monograph Reference for Chirality
• 21 CFR Part 210/211 (FDA cGMP for Finished Pharmaceuticals)
• EDQM CEP Requirements for Intermediates

Typical usage ratio

• 0.8–1.2 molar equivalents per target amine substrate; adjusted based on target yield and desired chiral purity

Downstream process integration

• Introduced during intermediate synthesis, typically after initial coupling reactions and prior to deprotection/hydrolysis steps
• Purification via crystallization or chromatography, QC for optical rotation and residual solvents

Final product types

• Pharmaceutical APIs (e.g., linezolid, tedizolid)
• Protected amino acid derivatives
• Non-racemic beta-lactam intermediates
• Chiral pharmaceutical building blocks

2. Active Agrochemical Intermediate Production

Leading crop protection firms employ this oxazolidine as a chiral source in the multi-step synthesis of select herbicides and fungicides. Its unique formyl function triggers stereoselective bond formation, resulting in improved bioactivity profiles and regulatory compliance in active ingredient development across EFSA and EPA oversight.

Industry compliance standards

• FAO/WHO JMPR Agricultural Pesticide Guideline
• EU Regulation (EC) No 1107/2009 for Plant Protection Products
• EPA 40 CFR Part 180: Tolerances and Exemptions for Pesticide Chemical Residues
• OECD Guidance Document No. 24 (GLP Compliance)

Typical usage ratio

• 1.0–1.5 molar equivalents per functionalized precursor, based on final target yield and required enantiomeric excess

Downstream process integration

• Applied at the chain-extension stage of synthesis, enabling key enantiomeric coupling through aldehyde condensation
• Subsequent hydrolysis and deprotection under mild conditions to retain chiral integrity before formulation

Final product types

• Enantioenriched herbicide actives
• Optically pure fungicide intermediates
• Chiral agrochemical building blocks
• Pesticide precursor formulations

3. Specialty Peptide Synthesis

Peptide custom manufacturers integrate this oxazolidine derivative as a protected aldehyde building block for asymmetric peptide fragment assembly. Its tert-butoxycarbonyl group allows chemoselective deprotection, while retaining formyl function for site-specific coupling. It enables better purity in solid-phase peptide synthesis (SPPS) and fine-tuning of downstream biologic activity.

Industry compliance standards

• ISO 13485 Quality Management System for Medical Devices (relevant for peptide APIs/diagnostics)
• ICH Q11 Development and Manufacture of Drug Substances
• USP General Chapter <1047> for Peptide Synthesis
• REACH Regulation—Registration for intermediates (where applicable)

Typical usage ratio

• 0.9–1.3 molar equivalents per amino acid coupling cycle; varies by SPPS resin loading and chain length

Downstream process integration

• Used during initial fragment elongation and side-chain protection in SPPS or in solution-phase synthesis
• Removal of the tert-butoxycarbonyl group after critical fragment completion, monitored by HPLC and mass spectrometry

Final product types

• Therapeutic peptides
• Peptide-based diagnostic reagents
• Chiral peptide intermediates
• Peptidomimetic lead compounds

4. Fine Chemical Research and Chiral Building Block Supply

Research institutions and catalogue chemical producers rely on this oxazolidine for asymmetric syntheses, method development, and proof-of-concept production. It acts as a key structure in forming advanced chiral scaffolds, supporting chemical development for new materials and life science innovation. These use cases involve stringent quality tracking and batch traceability to facilitate reproducible scientific output and compliance with chemical safety standards.

Industry compliance standards

• ISO 9001 Quality Management System for Fine Chemical Production
• OECD GLP Principles for Research Chemicals
• Chemical safety standards (e.g., GHS classification and labeling)
• REACH Notification for chemical intermediates

Typical usage ratio

• 0.5–2.0 molar equivalents, depending on study design, reaction development stage, and desired throughput

Downstream process integration

• Introduced in early-stage synthesis as a variable chiral selector and for aldehyde-driven bond formation
• Process tracked via NMR and GC–MS; unreacted material recycled where possible

Final product types

• Research-grade chiral intermediates
• Advanced fine chemical scaffolds
• Discovery toolkits for drug development
• Academic small molecule libraries